Novo Nordisk has its sights set on Mexico. The Danish drugmaker has put that country next on its list to debut liraglutide in its new guise as a weight-loss drug.
A commonly used epilepsy drug may be able to stop fatty liver disease and prevent Type 2 diabetes in obese people, according to a new study by Johns Hopkins researchers.
New genes identified by scientists at the University of Louisville in Kentucky may indicate a person's predisposition to excess abdominal fat, which can be an indicator of more serious health conditions, such as cardiovascular disease, Type 2 diabetes and cancer.
A team of investigators at the University of Queensland in Australia says it has found an inflammatory protein called PAR2 that builds up in the fat tissue of obese humans and rodents.
More than two years after Orexigen began a forced march back through a $100 million Phase III study for its weight drug Contrave, the biotech is back with the news that it scored the positive interim results it needs for a return trip to the FDA. And the drug developer says it can look ahead to a potential approval as early as June, 2014.
Austrian researchers have discovered a compound that may be able to activate a protein in the body to trigger fat burning.
Promising results from early-stage work on Zafgen's weight drug beloranib clear a path to a Phase IIb trial that can fine-tune the dose while taking more time to gauge the long-term impact of its treatment on weight and set the right tone for ongoing talks with investors about a new financing round for the biotech.
Eisai gave Arena Pharmaceuticals' obesity drug Belviq another vote of confidence. The Japanese drugmaker, already marketing the drug in the U.S., signed up to promote it in most other global markets, too. And it gave Arena a $60 million up-front payment to seal the deal.
GLP-1 drugs have long been one of the hottest targets in diabetes R&D, attracting the attention of the all of the giants that play in this blockbuster market. But now Roche has its eye on an early-stage program that could do GLP-1 drugs one better.
Analysts promised a battle of obesity drugs between Arena's Belviq and Vivus' Qsymia. But in marketing partner Eisai, Arena has a weapon Vivus lacks--and that weapon is about to get bigger. The Japanese company plans to add more than 200 sales reps to its army by December, doubling its size since the drug hit the market this June.